Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation

D. S. Ettinger, J. D. Bitran, R. L. Comis, C. J. Langer, K. V. Harwood, C. L. Harris, J. H. Keller, M. Losada

Research output: Contribution to journalArticle

Abstract

Sixty-five patients (20 patients who had had prior radiotherapy and 45 patients who had not had prior radiotherapy) were entered into a study evaluating escalating doses of etoposide and mitomycin in the treatment of non-small-cell lung cancer (NSCLC). Twenty-two percent of patients who had not received prior radiotherapy responded to the chemotherapy, compared with 5% of patients who had received prior radiotherapy. The best response rate and median survival time was 30% and 31.9 weeks, respectively, seen in three of 10 patients receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3. The major toxicity was hematologic - mainly leukopenia, in 59% of patients who had had no prior radiation therapy and were receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 150 mg/M2 i.v. days 1-3 (grade 3 and 4 hematologic toxicity). The mitomycin-etoposide drug combination has some activity in patients with NSCLC who have not received prior radiotherapy. The recommended starting dose is mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3, administered every 4 weeks.

Original languageEnglish (US)
Pages (from-to)127-132
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number2
DOIs
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation'. Together they form a unique fingerprint.

  • Cite this